Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN-002 in Healthy Subjects, Asthma, and COPD
NCT05006521Phase 1Completed
- Sponsor
- Kinaset Therapeutics
- Start
- Jul 2021
- Primary completion
- Dec 2023
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of frevecitinib in asthma and chronic obstructive pulmonary disease (COPD) (8 arms), sponsored by Kinaset Therapeutics. Primary endpoint: Adverse Events. Started Jul 2021; status: completed.
02
Drugs
frevecitinib
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05006521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05006521.